摘要
目的探讨肝硬化并发上消化道出血(UGIB)的临床危险因素及云南白药辅助治疗的效果。方法 74例肝硬化并UGIB的患者(出血组)随机分为对照组(36例)和观察组(38例),观察组加用云南白药,观察两组疗效。以125例无UGIB的肝硬化患者(非出血组)为对照,分析UGIB危险因素。结果肝功能、门静脉内径、脾脏厚度、食管静脉曲张程度是肝硬化并发UGIB的危险因素。观察组总有效率高于对照组(P<0.05),但死亡率无统计学差异(P>0.05)。结论肝功能分级、门静脉内径、脾脏厚度、食管静脉曲张程度是肝硬化并发UGIB的危险因素。联合应用云南白药可提高疗效,但不能降低死亡率。
Objective To explore the clinical risk factors of cirrhosis complicated with upper gastrointestinal bleeding （UGIB）, and the therapeutic effect of Yunnan Baiyao. Methods All 74 cases of patients with cirrhosis complicated with UGIB （bleeding group） were randomly divided into control group （36 cases） and observation group （38 cases）. The observation group were given Yunnan Baiyao treatment additional, and the efficacy of two groups were observed. 125 cases of cirrhosis patients without UGIB were enrolled as non-bleeding group, and the risk factors of UGIB were analyzed. Results Multivariate logistic regression analysis showed that liver function, portal vein diameter spleen thickness and esophageal varices were the risk factors of UGIB. The total effective rate of observation group was higher than that of control group （P 〈0.05）, but there was no statistically significant difference in mortality （P〉 0.05）. Conclusion Liver function, portal vein diameter, thickness of spleen are the risk factors for liver cirrhosis complicated with UGIB. Yunnan Baiyao combination can improve the efficacy, but not reduce the mortality.
出处
《中国现代医生》
2014年第7期20-22,25,共4页
China Modern Doctor
基金
浙江省医药卫生科学研究基金计划(2010KYA164)
关键词
肝硬化
上消化道出血
危险因素
云南白药
Cirrhosis
Upper gastrointestinal bleeding
Risk factor
Yunnan Baiyao
